Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 20;9(19):e017165.
doi: 10.1161/JAHA.120.017165. Epub 2020 Sep 21.

Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus

Ninna Hahn Tougaard  1 , Simone Theilade  1   2 , Signe Abitz Winther  1 , Nete Tofte  1 , Tarunveer Singh Ahluwalia  1 , Tine Willum Hansen  1 , Peter Rossing  1   3 , Marie Frimodt-Møller  1
Affiliations

Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus

Ninna Hahn Tougaard et al. J Am Heart Assoc. .

Abstract

Background The value of carotid-femoral pulse wave velocity (cfPWV) as risk factor for development of complications in type 1 diabetes mellitus remains to be determined. We investigated associations between cfPWV and renal outcomes, cardiovascular events, and all-cause mortality in people with type 1 diabetes mellitus. Methods and Results cfPWV was measured with SphygmoCor in 633 people with type 1 diabetes mellitus. Median (interquartile range) follow-up was 6.2 (5.8-6.7) years. End points included progression in albuminuria group, decline in estimated glomerular filtration rate (eGFR) ≥30%, end-stage kidney disease, cardiovascular event, mortality, and a composite renal end point. Hazard ratios (HRs) were calculated per 1-SD increase in cfPWV. Adjustments included age, sex, hemoglobin A1c, mean arterial pressure, body mass index, low-density lipoprotein cholesterol, smoking, urine albumin excretion rate, and eGFR. The cohort included 45% women, mean (SD) age was 54 (13) years, mean (SD) eGFR was 83.2 (27.9) mL/min per 1.73 m2, and mean (SD) cfPWV was 10.4 (3.3) m/s. Median (interquartile range) albumin excretion rate was 17 (17-63) mg/24 h. After adjustment, higher cfPWV was associated with increased hazard of progression in albuminuria (HR, 1.59; 95% CI, 1.10-2.32); decline in eGFR ≥30% (HR, 1.38; 95% CI, 1.06-1.79); cardiovascular event (HR, 1.31; 95% CI, 1.01-1.70); mortality (HR, 1.36; 95% CI, 1.00-1.85); and the composite renal end point (HR, 1.30; 95% CI, 1.04-1.63), but not with end-stage kidney disease (HR, 1.18; 95% CI, 0.62-2.26). Higher cfPWV was associated with steeper yearly increase in albumin excretion and steeper yearly decline in eGFR after adjustment (P=0.002 and P=0.01, respectively). Conclusions cfPWV was associated with increased hazard of renal outcomes, cardiovascular event, and mortality. cfPWV may be suited for risk stratification in type 1 diabetes mellitus.

Keywords: arterial stiffness; carotid-femoral pulse wave velocity; diabetic complications; type 1 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

S.A.W. reports that her salary during PhD employment was partly from Novo Nordisk. P.R. has received consultancy and/or speaking fees (to his institution) from AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Myers Squibb, Gilead, Eli Lilly, MSD, Merck, Mundi, Novo Nordisk, and Sanofi Aventis, and has received research grants from AstraZeneca and Novo Nordisk. The remaining authors have no disclosures to report.

Figures

Figure 1
Figure 1. Kaplan‐Meier survival plots for all‐cause mortality and for the composite renal end point in quartiles of carotid‐femoral pulse wave velocity.
Figure 2
Figure 2. Cumulative incidences of cardiovascular and renal outcomes with mortality as competing risk in quartiles of carotid‐femoral pulse wave velocity calculated with the Aalen‐Johansen estimator.
A, Cumulative incidence of progression in albuminuria group and all‐cause mortality. B, Cumulative incidence of estimated glomerular filtration rate (eGFR) decline and all‐cause mortality. C, Cumulative incidence of end‐stage kidney disease (ESKD) and all‐cause mortality. D, Cumulative incidence of cardiovascular events (CVEs) and death of other causes.
See this image and copyright information in PMC

References

    1. Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM, Eliasson B, Gudbjornsdottir S. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392:477–486. - PMC - PubMed
    1. Libby P. Report of the national heart, lung, and blood institute–national institute of diabetes and digestive and kidney diseases working group on cardiovascular complications of type 1 diabetes mellitus. Circulation. 2005;28(111):3489–3493. - PubMed
    1. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes. 2010;59:3216–3222. - PMC - PubMed
    1. Sandahl K, Nielsen LB, Svensson J, Johannesen J, Pociot F, Mortensen HB, Hougaard P, Broe R, Rasmussen ML, Grauslund J, et al. Increased mortality in a Danish cohort of young people with type 1 diabetes mellitus followed for 24 years. Diabet Med. 2017;34:380–386. - PubMed
    1. Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–1418. - PubMed